MK0767 and Sulfonylurea Combination Study (0767-027)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543491

2007_629

MK-0767-027

0767-027

Details and patient eligibility

About

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment

129 patients

Sex

All

Ages

21 to 78 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 Diabetes with inadequate glycemic control
On Sulfonylurea monotherapy
Male or non-pregnant Females
Age 21 to 78 years, inclusive
On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6

Exclusion criteria

History of Type 1 diabetes
Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents
Patients with history of or intolerance of PPAR-y agonists